Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
PHASE2
For patients with recurrent liver cancer after liver transplantation, the m...
Status
Unknown
Location
Department of Liver Transplantation, the Third Affiliated Hospital of Sun Yat-sen University
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
PHASE2
This phase II trial studies how well giving bevacizumab, radiation therapy,...
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
PHASE1
This study is designed to evaluate the efficacy and safety of sintilimab-be...
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
PHASE2
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor grow...
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer
PHASE2
This is a prospective, multi-center, randomized controlled clinical interve...
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
NA
The correlation between the values of angiogenesis-related growth factors i...